Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VCAM-1


Brief Information

Name:Vascular cell adhesion molecule 1
Target Synonym:VCAM1,Vascular cell adhesion protein 1,V-CAM 1,CD106,Vascular Cell Adhesion Molecule 1,CD106 Antigen,INCAM-100,VCAM-1,Vascular Cell Adhesion Molecule-1
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Immobilized Human VCAM-1, Fc Tag (Cat. No. VC1-H5253) at 5 μg/mL (100 μL/well) can bind Human ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W1) with a linear range of 5-156 ng/mL (QC tested).

VCAM-1 MALS images

The purity of Human VCAM-1, Fc Tag(Cat. No. VC1-H5253) is more than 85% and the molecular weight of this protein is around 204-260 kDa verified by SEC-MALS.

Synonym Name



Vascular cell adhesion protein 1 (VCAM1) is also known as CD106, INCAM-100 and L1CAM, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. VCAM1 / CD106 contains 7 Ig-like C2-type (immunoglobulin-like) domains. CD106 / VCAM-1 is expressed on inflammed vascular endothelium, as well as on macrophage-like and dendritic cell types in both normal and inflammed tissue. L1CAM / VCAM-1 is Important in cell-cell recognition and appears to function in leukocyte-endothelial cell adhesion. CD106 / VCAM1 interacts with the beta-1 integrin VLA4 on leukocytes, and mediates both adhesion and signal transduction. The VCAM1 / VLA4 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation. INCAM-100 / VCAM1 binds to ECMV-D capsid proteins and acts as a receptor for this virus.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tocopherol acetate DSE-9912 Approved National Institute Of Diabetes And Digestive And Kidney Diseases Ephynal, Aquasol E Mainland China Basf Health & Nutrition As, Basf (China) Co Ltd Beijing Office 2006-12-05 Non-alcoholic Fatty Liver Disease; Venous Thromboembolism; Atherosclerosis; Intermittent Claudication; Thrombosis; Diabetic Retinopathy Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
99mTccAbVCAM1‐5 99mTccAbVCAM1‐5 Phase 1 Clinical Medico-Economic Evaluation Unit , University Hospital, Grenoble Atherosclerosis Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message